{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T20:58:26Z","timestamp":1789160306758,"version":"build-2803163510"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,1,14]],"date-time":"2014-01-14T00:00:00Z","timestamp":1389657600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1471-2407-14-22","type":"journal-article","created":{"date-parts":[[2014,1,14]],"date-time":"2014-01-14T20:15:13Z","timestamp":1389730513000},"source":"Crossref","is-referenced-by-count":43,"title":["Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCceR trial): a multicenter randomised controlled study"],"prefix":"10.1186","volume":"14","author":[{"given":"Rafli","family":"van de Laar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra LM","family":"Zusterzeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toon","family":"Van Gorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marrije R","family":"Buist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willemien J","family":"van Driel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja N","family":"Gaarenstroom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henriette JG","family":"Arts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes CM","family":"van Huisseling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph HM","family":"Hermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna MA","family":"Pijnenborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eltjo MJ","family":"Schutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold MP","family":"Pelikan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos HA","family":"Vollebergh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam JA","family":"Engelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"IntHout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy FPM","family":"Kruitwagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon FAG","family":"Massuger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,1,14]]},"reference":[{"key":"4248_CR1","doi-asserted-by":"publisher","first-page":"S104","DOI":"10.1016\/S0959-8049(11)70154-X","volume":"47","author":"JA Ledermann","year":"2011","unstructured":"Ledermann JA, Raja FA: Clinical trials and decision-making strategies for optimal treatment of relapsed ovarian cancer. Eur J Cancer. 2011, 47: S104-S115.","journal-title":"Eur J Cancer"},{"issue":"9375","key":"4248_CR2","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","volume":"361","author":"MK Parmar","year":"2003","unstructured":"Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, et al: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial. Lancet. 2003, 361 (9375): 2099-2106.","journal-title":"Lancet"},{"issue":"Suppl 1","key":"4248_CR3","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/j.1525-1438.2005.15355.x","volume":"15","author":"J Pfisterer","year":"2005","unstructured":"Pfisterer J, Vergote I, Du Bois A, Eisenhauer E: Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer. Int J Gynecol Cancer. 2005, 15 (Suppl 1): 36-41.","journal-title":"Int J Gynecol Cancer"},{"issue":"17","key":"4248_CR4","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","volume":"30","author":"C Aghajanian","year":"2012","unstructured":"Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, Sovak MA, Yi J, Nycum LR: OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012, 30 (17): 2039-2045. 10.1200\/JCO.2012.42.0505.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4248_CR5","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.ygyno.2008.08.033","volume":"112","author":"RE Bristow","year":"2009","unstructured":"Bristow RE, Puri I, Chi DS: Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol. 2009, 112 (1): 265-274. 10.1016\/j.ygyno.2008.08.033.","journal-title":"Gynecol Oncol"},{"issue":"12","key":"4248_CR6","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1245\/s10434-006-9058-0","volume":"13","author":"P Harter","year":"2006","unstructured":"Harter P, du Bois A, Hahmann M, Hasenburg A, Burges A, Loibl S, Gropp M, Huober J, Fink D, Schroder W, et al: Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol. 2006, 13 (12): 1702-1710. 10.1245\/s10434-006-9058-0.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"4248_CR7","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1097\/IGC.0b013e31820aaafd","volume":"21","author":"P Harter","year":"2011","unstructured":"Harter P, Sehouli J, Reuss A, Hasenburg A, Scambia G, Cibula D, Mahner S, Vergote I, Reinthaller A, Burges A, et al: Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer. 2011, 21 (2): 289-295. 10.1097\/IGC.0b013e31820aaafd.","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"4248_CR8","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1245\/s10434-011-1873-2","volume":"19","author":"WJ Tian","year":"2012","unstructured":"Tian WJ, Chi DS, Sehouli J, Trope CG, Jiang R, Ayhan A, Cormio G, Xing Y, Breitbach GP, Braicu EI, et al: A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection. Ann Surg Oncol. 2012, 19 (2): 597-604. 10.1245\/s10434-011-1873-2.","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"4248_CR9","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.ejso.2010.04.012","volume":"36","author":"L Woelber","year":"2010","unstructured":"Woelber L, Jung S, Eulenburg C, Mueller V, Schwarz J, Jaenicke F, Mahner S: Perioperative morbidity and outcome of secondary cytoreduction for recurrent epithelial ovarian cancer. Eur J Surg Oncol. 2010, 36 (6): 583-588. 10.1016\/j.ejso.2010.04.012.","journal-title":"Eur J Surg Oncol"},{"key":"4248_CR10","volume-title":"Cochrane Database Syst Rev","author":"K Galaal","year":"2010","unstructured":"Galaal K, Naik R, Bristow RE, Patel A, Bryant A, Dickinson HO: Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer. Cochrane Database Syst Rev. 2010, 6: CD007822"},{"issue":"4","key":"4248_CR11","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1097\/IGC.0b013e31821bb8aa","volume":"21","author":"M Friedlander","year":"2011","unstructured":"Friedlander M, Trimble E, Tinker A, Alberts D, Avall-Lundqvist E, Brady M, Harter P, Pignata S, Pujade- Lauraine E, Sehouli J, et al: Clinical trials in recurrent ovarian cancer. Int J Gynecol Cancer. 2011, 21 (4): 771-775. 10.1097\/IGC.0b013e31821bb8aa.","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"4248_CR12","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009, 45 (2): 228-247. 10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"issue":"2","key":"4248_CR13","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","volume":"21","author":"GJ Rustin","year":"2011","unstructured":"Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, du Bois A, Kristensen G, Jakobsen A, Sagae S, et al: Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer. 2011, 21 (2): 419-423. 10.1097\/IGC.0b013e3182070f17.","journal-title":"Int J Gynecol Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-14-22.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-14-22\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-14-22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,7,12]],"date-time":"2016-07-12T22:06:21Z","timestamp":1468361181000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-14-22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,14]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["4248"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-14-22","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,14]]},"article-number":"22"}}